News

Latest valve and structural heart intelligence

50 articles from Cardiovascular Business
CVB
news·2 days ago·Cardiovascular Business

Self-expanding TAVR valves from Medtronic, Abbott consistently linked to positive outcomes

Self-expanding TAVR valves from Medtronic and Abbott demonstrate consistent positive clinical outcomes in comparative analyses. The findings support the sustained performance profile of these platforms in transcatheter aortic valve replacement procedures.

Digest: These data reinforce operator confidence in self-expanding valve technology and may influence device selection strategies among interventional cardiologists, particularly in anatomies where self-expanding platforms offer theoretical advantages.

TAVRMedtronicAbbottMarketRead original
CVB
trial·3 days ago·Cardiovascular Business

Abbott kicks off new research on software-guided, balloon-expandable TAVR system

Abbott has initiated new research on a software-guided, balloon-expandable transcatheter aortic valve replacement system. No specific clinical data or trial endpoints were provided in the article content.

Digest: Abbott's entry into balloon-expandable TAVR with software guidance could challenge Edwards and Medtronic's market dominance and potentially improve procedural precision and outcomes.

TAVRAbbottTrialImagingRead original
CVB
research·4 days ago·Cardiovascular Business

TAVR with a Trilogy valve shows promise for LVAD patients with AR

TAVR using the Trilogy valve demonstrated feasibility for treating aortic regurgitation in patients with left ventricular assist devices. The study represents a novel application of transcatheter techniques in a complex patient population with limited treatment options.

Digest: Addresses an unmet clinical need for LVAD patients who develop AR, a complication that complicates device management and has traditionally required high-risk open surgery.

TAVRHigh RiskEdwardsRead original
CVB
research·9 days ago·Cardiovascular Business

TAVR just as safe when performed by early-career operators

A study demonstrates that transcatheter aortic valve replacement procedures performed by early-career operators achieve safety outcomes comparable to those of experienced operators. This finding supports the broader adoption of TAVR technology and operator training programs.

Digest: This evidence may inform hospital credentialing decisions and training pathways for TAVR programs, potentially expanding procedural access as volumes continue to grow across risk categories.

TAVRTrialRead original
CVB
research·10 days ago·Cardiovascular Business

Heart surgery outperforms TAVR in new 5-year study of young, low-risk patients

A new 5-year study demonstrates superior outcomes for surgical aortic valve replacement (SAVR) compared to transcatheter aortic valve replacement (TAVR) in younger, low-risk patients with aortic stenosis. The longer-term follow-up data suggest SAVR maintains advantages over TAVR in this specific patient population.

Digest: These findings may influence treatment algorithms and guideline recommendations for younger, low-risk aortic stenosis patients where long-term durability and optimal outcomes are critical considerations.

TAVRSAVRLow RiskDurabilityRead original
CVB
news·11 days ago·Cardiovascular Business

Cardiologist explains why TAVR may be beneficial for select patients with moderate aortic stenosis

A cardiologist discusses the potential role of TAVR in treating select patients with moderate aortic stenosis, an indication that extends beyond current approved severe AS populations. The article explores clinical rationale for expanding TAVR use to patients with less advanced valvular disease.

Digest: Expansion of TAVR to moderate AS represents a significant potential market growth opportunity and would fundamentally shift treatment paradigms for earlier-stage aortic valve disease.

TAVRGuidelinesMarketRead original
CVB
regulatory·13 days ago·Cardiovascular Business

NCD and the dawn of a new era: What expanded TAVR coverage means for patient care

The CMS National Coverage Determination (NCD) has expanded Medicare coverage for transcatheter aortic valve replacement, broadening patient eligibility criteria beyond previous restrictions. This policy change enables reimbursement for TAVR in a wider population of patients with aortic stenosis, including potentially lower-risk cohorts previously subject to coverage limitations.

Digest: Expanded NCD coverage removes reimbursement barriers that may have limited TAVR adoption despite FDA approval across risk strata, potentially accelerating market penetration and influencing treatment decisions for structural heart teams.

TAVRReimbursementLow RiskRead original
CVB
trial·13 days ago·Cardiovascular Business

Medtronic studying safety, effectiveness of its self-expanding TAVR valves in patients with moderate AS

Medtronic has initiated a clinical study evaluating the safety and effectiveness of its self-expanding transcatheter aortic valve replacement (TAVR) systems in patients with moderate aortic stenosis. The trial represents an expansion into earlier-stage disease beyond current severe symptomatic AS indications.

Digest: This trial could potentially expand TAVR treatment paradigm to moderate AS patients, representing a significant market opportunity and earlier intervention strategy that would shift current guidelines recommending watchful waiting.

TAVRTrialMedtronicFDARead original
CVB
regulatory·17 days ago·Cardiovascular Business

FDA confirms new Class I recall for heart valve delivery system due to safety risk

The FDA has confirmed a new Class I recall for a heart valve delivery system due to identified safety risks. Class I recalls represent the most serious category, indicating reasonable probability that use of the product will cause serious adverse health consequences or death.

Digest: Class I recalls of transcatheter valve delivery systems can impact procedural planning, require device inventory checks, and may necessitate changes in implantation technique or device selection for structural heart teams.

CVB
research·18 days ago·Cardiovascular Business

New stroke prevention device for TAVR falls short, raising questions about the value of embolic protection

A new embolic protection device designed to prevent stroke during TAVR procedures failed to meet its clinical endpoints. The negative results call into question the overall clinical value and efficacy of embolic protection strategies in transcatheter aortic valve replacement.

Digest: This trial failure may influence adoption patterns of embolic protection devices in TAVR and could impact regulatory pathways and reimbursement decisions for this device class.

TAVRTrialFDARead original
CVB
research·20 days ago·Cardiovascular Business

Degenerative mitral valve disease: Key takeaways from the largest study of its kind

A large-scale study analyzed degenerative mitral valve disease patterns and outcomes, representing the largest cohort of its kind to date. The study provides comprehensive epidemiological and clinical data on disease progression, intervention timing, and patient outcomes in degenerative mitral regurgitation.

Digest: This dataset establishes important benchmarks for risk stratification and optimal timing of surgical or transcatheter mitral valve interventions in degenerative disease.

TMVRSurgicalGuidelinesRead original
CVB
news·20 days ago·Cardiovascular Business

TAVR linked to key benefits for select heart patients with moderate aortic stenosis

Transcatheter aortic valve replacement (TAVR) demonstrated clinical benefits in selected patients with moderate aortic stenosis, expanding potential indications beyond current severe stenosis criteria. The findings suggest TAVR may benefit a broader patient population than currently approved.

Digest: This represents a potential paradigm shift in TAVR eligibility that could significantly expand the treatable patient population and market, though awaits definitive trial data and regulatory consideration.

TAVRTrialGuidelinesFDARead original
CVB
research·21 days ago·Cardiovascular Business

EARLY TAVR update: New data highlight economic benefits of treating asymptomatic aortic stenosis

New health economic data from the EARLY TAVR trial demonstrate cost-effectiveness of transcatheter aortic valve replacement in patients with asymptomatic severe aortic stenosis. The analysis supports earlier intervention before symptom onset in appropriately selected patients.

Digest: Cost-effectiveness data may influence payer coverage decisions and clinical adoption of TAVR in asymptomatic patients, a potentially large untreated population that could significantly expand the structural heart market.

TAVRTrialReimbursementMarketRead original
CVB
trial·23 days ago·Cardiovascular Business

First patients treated for TRIUMPH trial focused on new TTVR tech

The TRIUMPH trial has enrolled and treated its first patients to evaluate a new transcatheter tricuspid valve replacement (TTVR) technology. This first-in-human milestone marks the initiation of clinical investigation for this novel device platform.

Digest: TTVR remains an emerging and technically challenging space with limited approved devices, making early-stage clinical trial data critical for assessing new competitive technologies entering the tricuspid intervention market.

TTVRTrialFirst-in-HumanRead original
CVB
trial·23 days ago·Cardiovascular Business

Abbott now enrolling patients for new research on Cephea mitral valve replacement device

Abbott has initiated patient enrollment for a new clinical study evaluating the Cephea transcatheter mitral valve replacement system. The trial represents continued development of Abbott's TMVR platform for treating mitral valve disease.

Digest: This enrollment milestone advances Abbott's competitive position in the developing TMVR market, where multiple platforms are vying for clinical validation and eventual regulatory approval.

TMVRAbbottTrialRead original
CVB
research·23 days ago·Cardiovascular Business

Long-term data support durability and sustained outcomes with balloon-expandable TAVR valves

Long-term follow-up data demonstrate sustained performance and structural durability of balloon-expandable transcatheter aortic valve replacement systems. The findings support extended valve longevity beyond initial trial periods.

Digest: Long-term durability data are critical for expanding TAVR into younger, lower-risk patient populations and supporting lifetime management strategies in structural heart disease.

TAVRDurabilityEdwardsRead original
CVB
research·24 days ago·Cardiovascular Business

Strokes after TAVR remain a problem: Key insights from new registry data

New registry data demonstrates that stroke remains a significant complication following transcatheter aortic valve replacement. The findings highlight the ongoing need for stroke prevention strategies in TAVR patients.

Digest: Stroke is a major adverse event that impacts TAVR outcomes, patient selection, and drives development of cerebral protection devices and anticoagulation strategies.

TAVRThrombosisAnticoagulationRead original
CVB
regulatory·25 days ago·Cardiovascular Business

FDA approves transcatheter device for treating PVL after heart surgery for first time

The FDA has granted first-time approval for a transcatheter device to treat paravalvular leak (PVL) following surgical valve replacement. This represents the first dedicated transcatheter solution approved for post-surgical PVL management.

Digest: This approval establishes a new minimally invasive treatment option for a complication that previously required redo surgery or off-label device use, addressing an unmet need in the post-surgical valve population.

FDASurgicalMinimally InvasiveRead original
CVB
news·30 days ago·Cardiovascular Business

Is surgical backup still necessary during TAVR? Opinions are mixed as bailout risk decreases

Debate continues regarding the necessity of on-site surgical backup during transcatheter aortic valve replacement procedures as complication rates requiring emergency conversion have decreased. The discussion reflects evolving procedural safety profiles and institutional experience with TAVR across different risk categories.

Digest: Resolution of the surgical backup requirement could expand TAVR availability to non-surgical centers and reduce procedural costs, though implications for patient safety and regulatory standards remain contentious.

TAVRSurgicalGuidelinesMarketRead original
CVB
news·about 1 month ago·Cardiovascular Business

SCAI's position on TAVR changes evolved after member survey

The Society for Cardiovascular Angiography and Intervention (SCAI) modified its official position statement regarding TAVR following feedback obtained through a membership survey. The society's evolving stance reflects input from its interventional cardiology membership base regarding contemporary TAVR practice and indications.

Digest: Professional society position statements from SCAI influence clinical practice patterns, institutional protocols, and regulatory considerations for TAVR utilization across risk categories.

TAVRGuidelinesSCAIRead original
CVB
research·about 1 month ago·Cardiovascular Business

TAVR linked to lower risk of in-hospital mortality than SAVR

A study found that transcatheter aortic valve replacement (TAVR) was associated with lower in-hospital mortality compared to surgical aortic valve replacement (SAVR). The analysis suggests improved short-term safety outcomes with the transcatheter approach.

Digest: This mortality data may influence treatment selection algorithms and further support TAVR expansion across risk categories, impacting procedural volumes and reimbursement strategies.

TAVRSAVRTrialRead original
CVB
regulatory·about 1 month ago·Cardiovascular Business

FDA approves Pascal Precision system from Edwards Lifesciences for tricuspid valve repair

The FDA has approved Edwards Lifesciences' Pascal Precision system for transcatheter tricuspid valve repair. This represents regulatory clearance for Edwards' edge-to-edge repair platform to treat tricuspid regurgitation.

Digest: This approval provides interventional cardiologists with another transcatheter option for treating tricuspid regurgitation, expanding the competitive landscape in the emerging TTVR market.

TTVREdwardsFDARegulatoryRead original
CVB
news·about 1 month ago·Cardiovascular Business

Surgeon highlights the historical significance of new adjustable heart valve for children

A cardiac surgeon discussed the historical importance of a newly developed adjustable heart valve designed specifically for pediatric patients with congenital heart disease. The valve represents a potential advancement in addressing the challenge of valve replacement in growing children who currently require multiple reoperations as they outgrow fixed-size prostheses.

Digest: Adjustable valves could reduce the burden of repeat surgeries in pediatric congenital heart disease patients, though broader structural heart professionals should note this addresses a distinct patient population from the adult degenerative valve market.

CongenitalSurgicalIndustryRead original
CVB
regulatory·about 1 month ago·Cardiovascular Business

FDA shares warning about Edwards Lifesciences heart valve tech after patient death

The FDA issued a safety warning regarding Edwards Lifesciences heart valve technology following a patient death. The agency is alerting healthcare providers and patients about potential safety concerns associated with the device.

Digest: FDA safety communications regarding transcatheter heart valve platforms can impact clinical decision-making, device utilization patterns, and inform risk-benefit discussions with patients undergoing valve interventions.

FDAEdwardsTAVRRead original
CVB
news·about 1 month ago·Cardiovascular Business

Cardiology’s busy year: Compensation, productivity, imaging volumes and TAVR cases all on the rise for heart specialists

Cardiology practices reported increased compensation, productivity, imaging volumes, and TAVR case volumes in the most recent reporting period. The data reflects growing demand for cardiovascular services with specific expansion in transcatheter aortic valve replacement procedures.

Digest: Rising TAVR volumes and cardiologist productivity metrics indicate sustained market growth and increasing procedural adoption, relevant for capacity planning and market forecasting in structural heart.

TAVRMarketImagingRead original
CVB
news·about 1 month ago·Cardiovascular Business

PCI before TAVR may still be safest strategy for some heart patients

A clinical strategy analysis suggests that performing percutaneous coronary intervention prior to transcatheter aortic valve replacement may remain the safest approach for select patients with concurrent coronary artery disease and aortic stenosis. The recommendation addresses ongoing debate about optimal timing and sequencing of coronary revascularization in TAVR candidates.

Digest: This guidance impacts preprocedural planning and patient selection for the growing TAVR population, particularly as indications expand to lower-risk patients who may have longer life expectancy and therefore greater concern about untreated coronary disease.

TAVRGuidelinesLow RiskRead original
CVB
regulatory·about 1 month ago·Cardiovascular Business

Physicians support Medicare coverage for TAVR in patients with aortic regurgitation

Physicians are advocating for Medicare coverage expansion to include transcatheter aortic valve replacement for patients with native aortic regurgitation. This represents a push to extend TAVR reimbursement beyond the currently covered indication of aortic stenosis.

Digest: CMS coverage for TAVR in aortic regurgitation would open a new market segment and provide reimbursement for an off-label use that some operators are already performing with dedicated or adapted devices.

TAVRReimbursementFDARead original
CVB
regulatory·about 1 month ago·Cardiovascular Business

JenaValve recalls certain TAVR delivery catheters over safety concerns

JenaValve has initiated a recall of certain delivery catheters used with its transcatheter aortic valve replacement system due to safety concerns. The specific nature of the safety issue and scope of affected devices were not detailed in the article.

Digest: Delivery catheter malfunctions during TAVR procedures can lead to procedural complications, deployment failures, or patient harm, making this recall clinically relevant for centers using JenaValve systems.

TAVRFDARegulatoryRead original
CVB
research·about 1 month ago·Cardiovascular Business

Sutureless aortic valve linked to positive 7-year data

A sutureless aortic valve replacement system demonstrated positive clinical outcomes at 7-year follow-up. The long-term data supports the durability and safety profile of sutureless valve technology in surgical aortic valve replacement.

Digest: Seven-year durability data for sutureless valves addresses a critical knowledge gap for cardiac surgeons considering this technology as an alternative to conventional SAVR, particularly in patients where reduced procedural time may be advantageous.

SAVRDurabilitySurgicalRead original
CVB
industry·about 2 months ago·Cardiovascular Business

Canon launches new TAVR technology to help structural heart programs meet rising demand

Canon has launched new TAVR technology designed to help structural heart programs address increasing procedural demand. No specific clinical data or device specifications were provided in the announcement.

Digest: New imaging or support technology from Canon could enhance procedural efficiency and capacity as TAVR volumes continue to expand across risk categories.

TAVRImagingMarketRead original
CVB
regulatory·about 2 months ago·Cardiovascular Business

CMS considers covering TAVR for aortic regurgitation

CMS is considering coverage for transcatheter aortic valve replacement (TAVR) in patients with aortic regurgitation. This would represent a significant expansion beyond the current approved indication of aortic stenosis.

Digest: CMS coverage for TAVR in aortic regurgitation would open a new market segment and provide reimbursement for an off-label use that has shown feasibility in selected patients but lacks robust trial data.

TAVRReimbursementFDACMSRead original
CVB
regulatory·about 2 months ago·Cardiovascular Business

FDA approves first heart valve that grows with children

The FDA has approved the first pediatric heart valve prosthesis designed to grow with children as they develop. This represents a significant advancement in congenital valve replacement, potentially reducing the number of reoperations required in pediatric patients.

Digest: This approval addresses a critical unmet need in pediatric structural heart disease by eliminating the requirement for multiple valve replacements as children grow, which could substantially reduce surgical burden and improve long-term outcomes.

FDACongenitalSurgicalRead original
CVB
regulatory·about 2 months ago·Cardiovascular Business

FDA clears video endoscope for select minimally invasive cardiac surgeries

The FDA has granted clearance for a video endoscope system intended for use in select minimally invasive cardiac surgical procedures. Specific procedural indications and device specifications were not detailed in the available content.

Digest: Enhanced visualization technology for minimally invasive cardiac surgery may facilitate adoption of less invasive surgical approaches for structural heart interventions, particularly minimally invasive surgical valve repair and replacement.

FDASurgicalMinimally InvasiveImagingRead original
CVB
regulatory·about 2 months ago·Cardiovascular Business

FDA clears AI tool for detecting undiagnosed heart valve disease in ECGs

The FDA cleared an artificial intelligence tool designed to detect undiagnosed valvular heart disease through analysis of standard 12-lead electrocardiograms. The AI algorithm enables screening for structural heart conditions using routine ECG data without requiring echocardiography.

Digest: This screening tool could facilitate earlier identification of valve disease patients who may be candidates for structural heart interventions, potentially expanding the treatable patient population.

FDAImagingMarketRead original
CVB
news·about 2 months ago·Cardiovascular Business

Persistent mitral regurgitation after TAVR more common among women than men

Women experience persistent mitral regurgitation following transcatheter aortic valve replacement at higher rates compared to men. This sex-based difference in post-TAVR outcomes suggests potential anatomical or procedural factors affecting mitral valve function differently between sexes.

Digest: Sex-specific differences in post-TAVR complications may influence patient selection, procedural planning, and surveillance protocols for structural heart teams performing TAVR procedures.

TAVRImagingRead original
CVB
research·2 months ago·Cardiovascular Business

TAVR timing: Waiting more than 6 months may hurt survival odds

Patients who wait longer than 6 months to undergo transcatheter aortic valve replacement after indication may experience worse survival outcomes. The study suggests timely TAVR referral and performance is associated with improved mortality rates compared to prolonged delays.

Digest: This finding reinforces the importance of streamlined TAVR referral pathways and may influence heart team decision-making regarding procedural timing and patient selection strategies.

TAVRGuidelinesRead original
CVB
research·2 months ago·Cardiovascular Business

Photon-counting CT accurately screens TAVR patients for signs of valve dysfunction

Photon-counting CT has been validated as an accurate screening tool for detecting valve dysfunction in patients who have undergone transcatheter aortic valve replacement. The imaging modality demonstrates improved diagnostic capability for assessing TAVR valve performance during follow-up.

Digest: Advanced imaging tools that can reliably detect early TAVR valve dysfunction are critical for optimizing long-term patient management and surveillance strategies as TAVR extends into younger, lower-risk populations.

TAVRImagingDurabilityRead original
CVB
news·2 months ago·Cardiovascular Business

Late-breaking clinical trials announced for TCT 2026 in San Diego

TCT 2026 conference organizers have announced the slate of late-breaking clinical trials to be presented in San Diego. The announcement indicates which studies will be featured, though specific trial names and data are not yet disclosed.

Digest: Late-breaking trial announcements at TCT typically include pivotal structural heart studies that influence clinical practice and regulatory decisions in the interventional cardiology field.

TrialTAVRTMVRRead original
CVB
regulatory·2 months ago·Cardiovascular Business

Medical societies, aging advocates share early reactions to new TAVR policies

Medical societies and aging advocacy groups have issued initial responses to new CMS coverage policies affecting transcatheter aortic valve replacement. The policy changes appear to modify reimbursement or coverage criteria for TAVR procedures.

Digest: CMS coverage determinations directly impact TAVR access, reimbursement dynamics, and patient selection strategies for structural heart programs nationwide.

TAVRReimbursementGuidelinesRead original
CVB
regulatory·2 months ago·Cardiovascular Business

CMS finalizes sweeping TAVR changes, including Medicare coverage for asymptomatic patients

CMS finalized a national coverage determination expanding Medicare coverage for transcatheter aortic valve replacement to include asymptomatic patients with severe aortic stenosis. This represents a significant broadening of the Medicare eligible patient population beyond the previous requirement for symptomatic disease.

Digest: This reimbursement expansion substantially increases the addressable market for TAVR and aligns Medicare coverage with current clinical practice patterns and recent trial evidence in asymptomatic severe AS patients.

TAVRReimbursementFDALow RiskRead original
CVB
regulatory·2 months ago·Cardiovascular Business

FDA clears new device for capturing debris during TAVR

The FDA has granted clearance for a new embolic protection device designed to capture debris during transcatheter aortic valve replacement procedures. This device aims to reduce the risk of periprocedural stroke by preventing particulate matter from reaching the cerebral circulation during valve deployment.

Digest: Embolic protection devices address a persistent clinical concern in TAVR, as stroke remains a significant complication affecting 1-3% of procedures and impacting patient outcomes and healthcare costs.

FDATAVRRegulatoryRead original
CVB
news·2 months ago·Cardiovascular Business

Heart failure before and after TAVR: New data point to ongoing concerns

New data reveal ongoing concerns about heart failure occurrence both before and after transcatheter aortic valve replacement procedures. The findings highlight persistent clinical challenges in managing heart failure in TAVR patient populations.

Digest: Heart failure remains a critical complication affecting TAVR outcomes and patient selection, with implications for pre-procedural optimization and post-procedural surveillance strategies.

TAVRTrialRead original
CVB
news·3 months ago·Cardiovascular Business

Surgeon performs first implant of semi-rigid annuloplasty ring for tricuspid valve repair

A surgeon completed the first implant of a semi-rigid annuloplasty ring for tricuspid valve repair. No additional clinical details, outcomes, or patient data were provided in the source material.

Digest: Represents a technical milestone in surgical tricuspid valve repair, though clinical significance cannot be assessed without device specifications, patient outcomes, or comparative data.

SurgicalTTVRRead original
CVB
news·3 months ago·Cardiovascular Business

‘This could be transformative’: Surgeon performs first US implant of heart valve still under FDA review

A cardiac surgeon performed the first US implant of an investigational heart valve device that is currently undergoing FDA review but has not yet received regulatory approval. The procedure represents an early access case under what is likely an FDA early feasibility study or expanded access protocol.

Digest: This signals advancement of a novel valve technology through US regulatory pathways and provides early clinical experience that may inform future FDA approval decisions and market adoption strategies.

FDATrialSurgicalRead original
CVB
industry·3 months ago·Cardiovascular Business

Medtronic invests up to $80M in medtech company Pi-Cardia with a potential buyout on the table

Medtronic announced an investment of up to $80 million in Pi-Cardia, a medical technology company, with a potential acquisition option included in the agreement. No specific clinical data or device performance metrics were disclosed in this announcement.

Digest: This strategic investment signals Medtronic's interest in expanding its structural heart portfolio through potential acquisition of Pi-Cardia's technology platform.

MedtronicMarketRead original
CVB
news·3 months ago·Cardiovascular Business

Tricuspid valve repair linked to major benefits for high-risk heart patients

Tricuspid valve repair demonstrated major clinical benefits in high-risk patients with significant tricuspid regurgitation. The study showed improved outcomes in this challenging patient population undergoing intervention.

Digest: Establishes evidence for tricuspid intervention in high-risk cohorts, supporting growing adoption of transcatheter and surgical repair techniques in an underserved valve disease population.

TTVRHigh RiskSurgicalRead original
CVB
news·3 months ago·Cardiovascular Business

TAVR and PCI: When heart patients need both, does the order matter?

The article addresses the clinical question of optimal sequencing when patients require both transcatheter aortic valve replacement (TAVR) and percutaneous coronary intervention (PCI). The content explores whether performing PCI before, during, or after TAVR affects procedural outcomes and patient safety.

Digest: Concomitant coronary artery disease is common in TAVR candidates, and determining the optimal revascularization strategy impacts procedural planning, resource allocation, and patient outcomes for interventional cardiologists.

TAVRGuidelinesRead original
CVB
research·3 months ago·Cardiovascular Business

No significant sex-based differences in timing of care for M-TEER patients

An analysis found no significant sex-based differences in timing of care for patients undergoing mitral transcatheter edge-to-edge repair (M-TEER). The study suggests that male and female patients receive similarly timed treatment access and procedural care.

Digest: Demonstrates equity in care delivery for M-TEER procedures across sexes, addressing ongoing concerns about potential gender disparities in access to advanced structural heart interventions.

TMVRTrialRead original
CVB
news·3 months ago·Cardiovascular Business

New TAVR risk score could help predict poor functional outcomes among older patients

A new risk scoring system has been developed to predict poor functional outcomes in older patients undergoing transcatheter aortic valve replacement. The score aims to improve patient selection and prognostication beyond traditional mortality risk assessments.

Digest: This tool could help structural heart teams better identify elderly TAVR candidates at risk for diminished quality of life or functional decline post-procedure, potentially improving shared decision-making and patient selection.

TAVRHigh RiskRead original
CVB
research·3 months ago·Cardiovascular Business

Redo TAVR with self-expanding valves linked to positive early outcomes

A study reports early positive outcomes in patients undergoing redo transcatheter aortic valve replacement procedures using self-expanding valve prostheses. The findings suggest self-expanding valves may be a viable option for treating failed prior TAVR procedures.

Digest: This addresses a growing clinical challenge as the first generation of TAVR patients develop structural valve deterioration requiring reintervention, informing valve selection strategies for redo procedures.

TAVRRedo-TAVRDurabilityMedtronicRead original